NCT/Study#
NCT05308264 /
C-906289-002
An Open-label, Phase 1b Study of study drug in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies
DISEASE GROUP:
Leukemia
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
